Company Overview
TEMPUS AI INC (TEM)
- Sector: Health Care
- Primary Exchange: Nasdaq
- Currency: USD
- Market Capitalization: $9.33 billion
- Price‑to‑Earnings Ratio: –30.33
- Recent Share Price: $56.14 (closed 2026‑06‑25)
- 52‑Week High/Low: $104.32 (2025‑10‑08) / $41.73 (2026‑03‑29)
Recent Strategic Development
On 25 June 2026, TEMPUS AI announced a partnership with Angiosarcoma Awareness to support enhanced research into angiosarcoma, a rare and aggressive cancer. The collaboration aims to leverage TEMPUS AI’s data‑driven diagnostic platform to accelerate biomarker discovery and therapeutic development for patients with this disease.
Investor Activity
- Cathie Wood, ARK Invest increased its position in TEMPUS AI on 25 June 2026, adding shares that reflected a 5.64 % gain in the company’s stock on that day.
- The purchase was part of a broader portfolio adjustment that included new positions in other AI‑focused companies (e.g., Cerebras Systems, Recursion Pharmaceuticals) and divestments from non‑AI holdings such as Alibaba Group and Roku.
- No specific trade quantity or dollar value for the TEMPUS AI transaction was disclosed in the source material.
Market Performance
- TEMPUS AI’s share price closed at $56.14 on 25 June 2026.
- The stock experienced a 5.64 % increase on 25 June 2026, coinciding with the ARK Invest purchase.
- Historically, the stock has ranged from a 52‑week low of $41.73 to a 52‑week high of $104.32.
Summary
TEMPUS AI INC, a Nasdaq‑listed health‑care technology company with a market cap of approximately $9.33 billion, has entered a strategic partnership focused on angiosarcoma research. Recent investor activity, notably by ARK Invest, has added momentum to the stock, which closed at $56.14 on 25 June 2026 after a 5.64 % increase. The company’s financial metrics and market performance indicate ongoing volatility typical of AI‑driven biotech firms.
